Abstract:
Background The impact of vitamin D on COVID-19 infection has been much discussed recently. Our aim was to evaluate the association between baseline serum 25(OH)D with severity of COVID-19.

Method This was an prospective study, where 174 COVID-19 in-patients of an academic hospital in an urban setting were enrolled from Aug, 2020 to Oct, 2020. After detailed clinical history taking and examination, patients were divided into mild, moderate, severe and critical categories. Vitamin D level was measured. Relation between level of vitamin D and disease severity was determined.

Result Mean age of the study population was 52.01 years. 13% mild, 22.99% moderate, 26.44% severe and 3.45% were critical cases. 76% of the patients had vitamin D deficiency. No statistical significance between the level of vitamin D and disease severity was seen (p=0.430).

Conclusion Our study revealed there is no correlation between vitamin D deficiency and severity of COVID-19.

Key words: SARS-CoV-2, COVID-19, Vitamin-D, Disease severity

Introduction: Coronavirus disease 2019 (COVID-19), a potentially severe acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared pandemic by World Health Organization (WHO) on 11th March 2020 following its outbreak as a cluster of pneumonia cases with unknown cause in Wuhan City, Hubei Province, China, in December 20191-4. In most cases the clinical presentation is that of a respiratory infection with a symptom severity ranging from a mild influenza like illness, to a severe viral pneumonia leading to acute respiratory distress syndrome that is potentially fatal. The explanations for this extremely variable prognosis are unclear. So far 114 M cases of COVID-19 were detected around the globe, among which 2.53 M deaths occurred. In Bangladesh 546k cases were detected, where 8400 deaths occurred5.

Vitamin – D, a fat soluble vitamin, has the classic endocrine effect on calcium and phosphate metabolism and bone health. It is important for maintaining normal function of the cardiac muscle, immune function, inflammation, as well as cell proliferation and differentiation. Apart from sunlight exposure, oily fish – such as salmon, sardines, herring and mackerel, red meat,
liver, egg yolks, fortified foods and dietary supplements are the sources of vitamin D⁶-⁸.

Mortality from coronavirus disease 2019 (COVID-19) is higher amongst people who are older, male, obese, diabetic, hypertensive, or who are from black, Asian, or minority ethnic (BAME) demographics, all these factors are associated with increased prevalence of vitamin D deficiency, with reduced impact of vitamin D on the immune response⁹. Interest in the potential for vitamin D supplementation to reduce risk of acute respiratory infections (ARI) has increased since the emergence of the COVID-19 pandemic¹⁰. Findings of laboratory studies showed that vitamin D metabolites support innate immune responses to respiratory viruses¹¹. Many observational studies have reported independent associations between low circulating levels of 25-hydroxyvitamin D and increased risk of ARI caused by other pathogens¹²,¹³. Randomized controlled trials (RCTs) of vitamin D for the prevention of ARI have produced heterogeneous results, with some showing protection, and others reporting null findings. One meta-analyzed individual participant data from 25 RCTs showed a protective overall effect that was stronger in those with lower baseline 25(OH)D levels, and in trials where vitamin D was administered daily or weekly rather than in more widely spaced bolus doses¹¹-¹⁵. We therefore sought data from these more recent studies for inclusion in an updated meta-analysis of aggregate (trial-level) data to determine whether vitamin D reduced ARI risk overall, and to evaluate whether effects of vitamin D on ARI risk varied according to baseline 25(OH)D concentration and/or dosing regimen (frequency, dose size, and trial duration). Many studies show that vitamin D has a potential role in the prevention or treatment of acute respiratory infection. Lower circulating 25(OH)D concentration has also been reported to associate susceptibility and severity to SARS-CoV-2 infection.

A potential crude association is found between the mean Vitamin D levels in various European countries with COVID-19 cases and COVID-19 mortality¹⁶. It is found that treatment with Cholecalciferol booster therapy regardless of baseline serum 25(OH)D levels, appeared to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19¹⁷. From one study it has been found that Lower latitude and typically ‘sunny’ countries such as Spain and Italy (Northern region), had low mean 25(OH)D and high deficiency, as well as higher infection and death rate of COVID-19. On the other hand, Countries having higher latitude (Norway, Finland, Sweden) which receive less UVB sunlight had higher mean 25(OH)D, low deficiency, and lower infection and mortality rate of COVID19¹⁸.

From another study it was yielded that Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity¹⁹. The National Institute for Health and Care Excellence (NICE) conducted a rapid review which confirms that currently there is not enough available evidence to determine that there is a causal relationship between vitamin D and COVID-19²⁰. Hypovitaminosis D is common among the real-world clinical subjects in Bangladesh²¹. The prevalence of vitamin D deficiency among the Bangladeshi population was found to be 100% in all age groups, particularly in female sex, urban & obese population²². So Bangladesh will be an ideal place to evaluate whether there is any relationship of low Vitamin D level to increased severity of disease in COVID-19 infection.

This study was aimed at determining the Vitamin-D levels among all mild, moderate, critical & Severe COVID-19 cases admitted in a dedicated COVID 19 care hospital in Bangladesh and to observe any relationship between vitamin D level and severity of COVID-19 infection.

Methods:
This was an observational prospective study conducted from August, 2020 - October, 2020 at 500 Bedded General Hospital, Mugda, Dhaka, Bangladesh, which is a COVID dedicated tertiary care hospital since April 20, 2020. Total 174 patients were recruited by purposive sampling. Figure 1 shows the entire method of study population selection.

To be included in this study, patients of both sexes need to fulfill all four of the following criteria – confirmed case of COVID-19 by positive RT-PCR, the patient has to be more than 18 years old, and the patient has to give informed written consent. Patients meeting the following criteria were excluded from the study – patients having history of taking vitamin D supplement within the last one month, patient having advanced malignancy and/or CLD, chronic pancreatitis, on drugs that can reduce
vitamin D, patient on dialysis, and if the patient is pregnant. Institutional ethics committee approved data collection and analysis. A preformed questionnaire was used for data collection.

Fig.-1: Study population selection

Patients were tested for SARS-CoV-2 by taking nasopharyngeal/oropharyngeal swabs using Sansure kits (Changsha, Hunan, China). RT-PCR was performed on Quantstudio 5, Thermofisher, USA in our hospital lab. Vitamin D was analyzed by chemiluminescence immunoassay (CLIA) method using Maglumi 2000 Plus, Snibe (Shenzhen, China) in other designated labs. About 10% samples of vitamin-D were rechecked in another laboratory for quality assurance.

Vitamin D insufficiency was defined as serum 25(OH)D level <30 ng/mL.26 Patients’ disease severity was labeled as mild, moderate, severe and critical as per WHO guideline Supportive care and treatment was given according to the National Guideline for Management of COVID-19 Version 7. All patients were followed up to discharge or death.

Results:
Total 174 cases were included in this study. Male (n=107, 61.49%) patients were higher than females (n=67, 38.51%). Most of the patients were above 40 years of age.

According to disease severity, there were 47.13% mild, 22.99% moderate, 26.44 % severe, and 3.45 % critical cases. In terms of clinical characteristics, fever was the most common symptom 84%, followed by cough 73.5% and sore throat 51%. Diarrhea, one of the most important GI symptoms, was found in 15% cases. Diabetes mellitus (DM) and hypertension (HTN) were two most common comorbidity. Almost half of the study subjects had hypertension (49.43%) and diabetes (47.7%).

75.86% of the study population had either deficient or insufficient levels of vitamin D (0-30 ng/mL) and 24.14% had sufficient levels of vitamin D (>30 ng/mL). Table 1 shows the vitamin D level among various groups of patients with their statistical significance (if any).

There was no difference in case severity of disease among both sexes \( \chi^2 = 1.59, \text{df 3, } p=0.660 \). An independent T test revealed

Table-I

| Variable ( % )     | Mean Vitamin D Level (ng/mL ± SD) | p Value |
|--------------------|----------------------------------|---------|
| Male (61.49)       | 27.47 ± 8.81                     | <0.001  |
| Female (38.51)     | 22.90 ± 6.64                     |         |
| Age <40 years (26.44) | 24.85 ±7.33                      | 0.441   |
| Age >40 years (73.56) | 25.95 ±9.84                      |         |
| Patient with DM (47.7) | 25.92 ±6.12                      | 0.698   |
| Patient without DM (52.3) | 25.43 ±6.34                     |         |
| Patient with HTN (49.43) | 26.13 ±5.63                      | 0.462   |
| Patient without HTN (50.57) | 25.20 ±5.71                     |         |
| Patient requiring ICU (7.47) | 26.74 ±5.84                      | 0.628   |
| Patient not requiring ICU (92.53) | 25.57 ±8.49                  |         |
| Patient who didn’t survive (4.6) | 28.24 ±5.11                      | 0.371   |
| Patient who survived (95.4) | 25.54 ±8.89                      |         |
| Mild case (47.13)  | 26.68 ±10.46                     | 0.430   |
| Moderate case (22.99) | 24.13 ±5.30                      |         |
| Severe case (26.44) | 25.15 ±6.04                      |         |
| Critical case (3.45) | 25.94 ±5.85                      |         |

the average vitamin D level of male was significantly higher than female, p<0.001. Vitamin D level in patients admitted in ICU was rather higher than patients who didn’t require ICU admission. This difference was not statistically significant (p=0.628).

An ANOVA test was conducted using the level of vitamin D as dependent variable and Severity of disease (mild, moderate, severe, critical) as independent variable. It revealed that there was no statistically significant different level of vitamin D in different
groups of disease severity. \( F(3,170) = 0.925, p = 0.430 \). Quantitative data were expressed as mean ± 2SD. Categorical variable is expressed as number (%). \( p \) - value of <0.05 was considered statistically significant. Independent sample t-test, Pearson’s chi square test and ANOVA were performed. All statistical analysis were done by using SPSS version-21 (IBM SPSS Inc, Chicago IL)

**Discussion**

Our study demonstrated no association between level of vitamin D and severity of SARS-CoV-2 infection. Faul et al.\(^{23}\) in their study on 33 patients with SARS-CoV-2-related pneumonia reported that VitD deficiency (baseline 25(OH)D < 12 ng/mL) was associated with a significantly increased risk for IMV, which does not match with our findings. Study from the UK that included 449 subjects (from the UK Biobank) with confirmed COVID-19 infection did not find an association between level of vitamin D and the risk of viral infections as well as COVID-19 infection.\(^{24}\) We found Fever (84%) was the most common symptom followed by cough (73.5%). Similar findings observed by Chaomin Wu et al.\(^{25}\) where fever (93.5%) and cough (73.5%) were two most common symptoms. Ranil Jayawardena et al. observed more than three quarter of study population had vitamin D insufficiency.\(^{26}\) We observed more than three quarter of study population had vitamin D insufficiency. Ranil Jayawardena et al.\(^{27}\) observed three quarter of the Asian countries, more than 50% of the adult population were vitamin D deficient. The lowest rate of vitamin D deficiency was reported in Vietnam with only 2.0% and the highest was reported in Oman at 87.5% . As expected, an inverse relationship was observed between the prevalence of VDD and mean VD levels and the countries, Oman and Vietnam had the lowest (32.5/ nmol/l) and the highest (83.8/ nmol/l) mean VD levels respectively. Mean vitamin D level in male was 27.47±8.81 and female was 22.90 ± 6.64 , which was statistically significant (\( P=0.001 \)). In one study by Monica Verdoia et al. noticed female gender was associated with lower vitamin D levels (14.5 ± 10.9 vs. 15.9 ± 9.5, \( p = 0.007 \)) and independently associated with severe vitamin D deficiency (41.9% vs. 30.4%, \( p<0.001 \))\(^{28}\). Another study by GK Acherjya et al. conducted study in Jashore, Bangladesh and noticed the mean serum 25(OH)D levels was 18.60±6.59ng/dl whereas in female the corresponding figure was 17.74±6.07gm/dl and no significant difference observed among the man and women (\( p=0.059 \))\(^{27}\).

**Conclusion:**

From this study we came to know that vitamin D deficiency is very common in our country, as only one fourth of study population had sufficient level of vitamin D. Females have significantly low level than males. No relation could be established between level of vitamin D with severity of disease or mortality. Our finding contrasted with many other studies, so further study with large sample to be conducted to resolve the issue.

**References:**

1. World Health Organization. Novel coronavirus—China2020. Accessed at www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/ on 30 March 2020
2. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-574
3. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-273.
4. Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733.
5. https://www.google.com/search?q=covid+19+statistics&aq=chrome.69i57j0f9.8603j1j15&sorceid=chrome&ie=UTF-8
6. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.
7. Norman AW, Henry HH. Vitamin D In: Erdman JW, Macdonald IA, Zeisel SH, eds. Present Knowledge in Nutrition, 10th ed. Washington DC: Wiley-Blackwell, 2012.
8. Jones G. Vitamin D In: Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR, eds. Modern Nutrition in Health and Disease, 11th ed. Philadelphia: Lippincott Williams & Wilkins, 2014.
9. J M, SubramanianS, Laird E et al. Perspective: Vitamin D deficiency and COVID-19 severity-J Intern Med.2020 July 2;10.1111/jim.13149
10. Lanham-New SA, Webb AR, Cashman KD, et al. Vitamin D and SARS-CoV-2 virus/COVID-19 disease. BMJ Nutrition, Prevention & Health 2020 doi: http://dx.doi.org/10.1136/bmjnph2020-00089
11. Greirler CL, Martineau AR. Modulation of the Immune Response to Respiratory Viruses by Vitamin D. Nutrients 2015;7(6):4240-70. doi: 10.3390/nu7064240
11. Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid BiochemMolBiol 2013;136:321-9. doi: 10.1016/j.jsbmb.2012.11.017 [published Online First: 2012/12/12]

12. Pham H, Rahman A, Majidi A, et al. Acute Respiratory Tract Infection and 25-Hydroxyvitamin D Concentration: A Systematic Review and Meta-Analysis. International journal of Environmental Research and Public Health 2019;16(17) doi: 10.3390/ijerph16173020 [published Online First: 2019/08/24]

13. Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect 2009;137(10):1396-404. doi: 10.1017/S0950268809002404 [published Online First: 2009/03/20]

14. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017;356:i6583. doi: 10.1136/bmj.i6583 [published Online First: 2017/02/17]

15. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res. 2020 Jul;32(7):1195-1198. doi: 10.1007/s40520-020-01570-8. Epub 2020 May 6. PMID: 32377965; PMCID: PMC7202265.

16. Ling SF, Broad E, Murphy R, Pappachan JM, Pardesi-Newton S, Kong MF, Jude EB. High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study. Nutrients. 2020 Dec 11;12(12):3799. doi: 10.3390/nu12123799. PMID: 33322317; PMCID: PMC7763301.

17. Laird E, Rhodes J, Kenny RA. Vitamin D and Inflammation: Potential Implications for Severity of Covid-19. Ir Med J. 2020 May 7;113(5):81. PMID: 32603576.

18. Panagiotou G, Tee SA, Ihsan Y, et al. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity. Clin Endocrinol (Oxf). 2020;93(4):508-511. doi:10.1111/cen.14276

19. https://www.medscape.com/viewarticle/942809#vp_1

20. Islam AKM, Hasan M A, Rahman M N et al. Vitamin D status in Bangladeshi subjects: a laboratory based study. BIRDEM Med J 2019; 9(3): 202-206

21. Hossain H T, Islam Q T,2 Md. Khandaker A K et al. J Study of Serum Vitamin D Level in Different Socio-Demographic Population - A Pilot Study. J Medicine 2018; 19: 22-29

22. Ranil JayawardenaDhanushya T. JeyakumarTormallii V. FrancisAnoop Misra. Impact of the vitamin D deficiency on COVID-19 infection and morality in Asian countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. https://doi.org/10.1016/j.dsx.2021.03.006

23. . Faul, J.L.; Kerley, C.P.; Love, B.; O’Neill, E.; Cody, C.; Tormey, W.; Hutchinson, K.; Cormican, L.J.; Burke, C.M. Vitamin D Deficiency and ARDS after SARS-CoV-2 Infection. Ir. Med. J. 2020, 113, 84. [PubMed]

24. Hastie, C.E., Mackay, D.F., Ho, F., Celis-Morales, C.A., Katikireddi, S.V., Niedzwiedz, C.L., Jani, B.D., Welsh, P., Mair, F.S., Gray, S.R. et al. (2020) Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr, 14, 561 -565.

25. Chaomin Wu, MD1,2,3; Xiaoyan Chen, MD3; Yanping Cai, MD2; et al, Risk factors associated with acute respiratory distress syndrome and death in patient with corona virus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943. doi:10.1001/jamainternmed.2020.0994

26. 26.G K Acherjya 1, M Ali, K Tarafder, N Akhter, M K Chowdhury, D U Islam, M H Rahman, M T Miah Study of Vitamin D Deficiency among the Apparently Healthy Population in Jashore, Bangladesh. Mymensingh Med J 2019 Jan;28(1):214-221.

27. Monica Verdoia, Alon Schaffer, Lucia barbieri, Gabriella Di Giovine. Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease. Nutrition Metabolism and Cardiovascular Diseases February 2015:25(5) DOI:10.1016/j.numecd.2015.01.009